May 7, 2020 -- Engineering biology company Sherlock Biosciences has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for a detection kit for the novel coronavirus using CRISPR, a gene-editing technology.
The Sherlock CRISPR SARS-CoV-2 kit uses technology that programs a CRISPR molecule to identify the presence of the virus's genetic signature from a nasal swab, nasopharyngeal swab, oropharyngeal swab, or bronchoalveolar specimen. The test is designed for CLIA-certified laboratories and can provide COVID-19 diagnostic results in about one hour, according to the company.
Sherlock is also working on developing an instrument-free handheld test for the novel coronavirus. The test, which will use Sherlock's Inspectr platform, will work similarly to an at-home pregnancy test to rapidly detect SARS-CoV-2's genetic signature.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current